Investing.com -- Alphatec Holdings (NASDAQ:ATEC) stock fell 21% on Monday after the spine-focused medical device company’s 2026 revenue growth guidance disappointed investors, despite reporting preliminary 2025 results that modestly beat expectations.
The Carlsbad, California-based company expects full-year 2026 revenue of $890 million, representing approximately 17% growth compared to 2025. This growth rate falls below the company’s historical 20%+ performance, causing concern among investors, even though the forecast actually exceeds the current analyst consensus of $886.9 million.
Alphatec reported preliminary 2025 total revenue growth of approximately 25% to $764 million, with surgical revenue growing 26% on the back of 24% surgical volume growth and 2% average revenue per procedure growth. The company reaffirmed its full-year 2025 adjusted EBITDA guidance of $91 million and expects fourth-quarter free cash flow between $6 million and $8 million.
For 2026, Alphatec projects adjusted EBITDA of approximately $130 million, in line with current Street projections, and expects to generate about $20 million in free cash flow.
"ATEC posted 20-21% top-line growth for 4Q, modestly outperforming 18% Consensus and reaffirmed 2025 adjusted EBITDA guidance of $91M was in-line. Shares are trading off in reaction to sub-20% 2026 revenue growth guidance, but implied revenues of $893.2-894.3M actually land above current Consensus at $886.9M. We see multiple drivers into 2026 and remain bullish on the Valence launch. Reiterate Buy," wrote TD Cowen analyst Joshua Jennings.
The company also announced the acquisition of exclusive U.S. distribution rights for Theradaptive’s OsteoAdapt, a next-generation rhBMP-2 solution designed to deliver more precise bone formation at fusion sites with improved safety profiles compared to legacy biologics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.















